ARTICLE | Company News
Lead Discovery Center, Qurient deal
July 13, 2015 7:00 AM UTC
Lead Discovery Center (LDC) granted Qurient exclusive, worldwide rights to develop cyclin dependent kinase 7 (CDK7) inhibitors to treat cancer, inflammation and viral infection. LDC will receive an un...